Frailty Assessment Before Cardiac Surgery & Transcatheter Interventions
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT01845207 |
Recruitment Status :
Completed
First Posted : May 3, 2013
Last Update Posted : August 31, 2016
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease |
---|
Aortic Stenosis Cardiac Valve Replacement Complication Fragility |
Study Type : | Observational [Patient Registry] |
Estimated Enrollment : | 800 participants |
Observational Model: | Cohort |
Time Perspective: | Prospective |
Target Follow-Up Duration: | 1 Year |
Official Title: | Frailty Assessment Before Cardiac Surgery & Transcatheter Interventions |
Study Start Date : | January 2012 |
Actual Primary Completion Date : | December 2014 |
Actual Study Completion Date : | March 2016 |

Group/Cohort |
---|
Aortic valve replacement
Patients aged ≥70 years referred for surgical or transcatheter aortic valve replacement.
|
- Post-procedural mortality or major morbidity [ Time Frame: 30 days ]Mortality is defined as death from any cause. Major morbidity is defined as an aggregate of the Society of Thoracic Surgeons (STS) and Valve Academic Research Consortium (VARC) composite endpoints. Additionally, the individual components of this composite endpoint will be examined.
- All-cause mortality [ Time Frame: 6-12 months ]
- Functional status [ Time Frame: 6-12 months ]
- Length of stay [ Time Frame: 30 days ]
- Cognitive function [ Time Frame: 6-12 months ]
- Mood disturbance [ Time Frame: 6-12 months ]
- Delirium [ Time Frame: 30 days ]
- Disposition [ Time Frame: 30 days ]
- Readmission [ Time Frame: 6-12 months ]
- Cost analysis and resource use [ Time Frame: 30 days ]
- Echocardiographic function of ventricles and valves [ Time Frame: 30 days ]
- Longitudinal recovery of physical and cognitive functioning [ Time Frame: Monthly (1-12 months) ]
Biospecimen Retention: Samples Without DNA

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 70 Years and older (Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Sampling Method: | Non-Probability Sample |
Inclusion Criteria:
- Age ≥70 years (a site-specific substudy at the JGH will enroll ages ≥21 years)
- Severe AS
- Referred for surgical or transcatheter AVR (with or without concomitant revascularization)
- Signed informed consent
Exclusion Criteria:
- Emergency surgery
- Clinical instability: decompensated heart failure, active ischemia, unstable vital signs
- Severe neuropsychiatric impairment
- Not English or French speaking
- Replacement of >1 valve or aortic surgery

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01845207
United States, Massachusetts | |
Massachusetts General Hospital | |
Boston, Massachusetts, United States, 02114 | |
Brigham & Women's Hospital | |
Boston, Massachusetts, United States, 02115 | |
Beth Israel Deaconess Medical Center | |
Boston, Massachusetts, United States, 02215 | |
United States, North Carolina | |
Duke University Medical Center | |
Durham, North Carolina, United States, 27705 | |
Canada, British Columbia | |
St. Paul's Hospital | |
Vancouver, British Columbia, Canada | |
Canada, Manitoba | |
St. Boniface Hospital | |
Winnipeg, Manitoba, Canada | |
Canada, Ontario | |
Hamilton General Hospital | |
Hamilton, Ontario, Canada | |
Ottawa Heart Institute | |
Ottawa, Ontario, Canada | |
St. Michael's Hospital | |
Toronto, Ontario, Canada | |
Canada, Quebec | |
Jewish General Hospital | |
Montreal, Quebec, Canada, H3T 1E2 | |
Centre Hospitalier Universite de Montreal | |
Montreal, Quebec, Canada | |
Montreal Heart Institute | |
Montreal, Quebec, Canada | |
Royal Victoria Hospital | |
Montreal, Quebec, Canada | |
France | |
Hôpital Jacques Cartier | |
Massy, France, 91300 |
Principal Investigator: | Jonathan Afilalo, MD MSc | Jewish General Hospital |
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: | Jonathan Afilalo, MD MSc FACC FRCPC, Jewish General Hospital |
ClinicalTrials.gov Identifier: | NCT01845207 |
Other Study ID Numbers: |
MOP-123314 |
First Posted: | May 3, 2013 Key Record Dates |
Last Update Posted: | August 31, 2016 |
Last Verified: | August 2016 |
Aortic stenosis Aortic valve replacement Transcatheter aortic valve implantation |
Outcomes Frailty Elderly |
Aortic Valve Stenosis Frailty Pathologic Processes Aortic Valve Disease |
Heart Valve Diseases Heart Diseases Cardiovascular Diseases Ventricular Outflow Obstruction |